- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05305664
En multicenterstudie som utvärderar effekten av sänkning av lipoprotein(a) med Pelacarsen (TQJ230) på frekvensen av veckovisa lipoproteinaferessessioner hos patienter med hyperlipoproteinemi(a) och etablerad kardiovaskulär sjukdom i Tyskland
En randomiserad, dubbelblind, placebokontrollerad, multicenterstudie som bedömer minskningen av frekvensen av lipoproteinaferes efter behandling med Pelacarsen (TQJ230) jämfört med placebo hos patienter med hyperlipoproteinemi(a) och etablerad hjärt-kärlsjukdom som genomgår veckovis lipoproteinapheres i Tyskland
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Berlin, Tyskland, 13353
- Novartis Investigative Site
-
Cloppenburg, Tyskland, 49661
- Novartis Investigative Site
-
Erlangen, Tyskland, 91054
- Novartis Investigative Site
-
Mainz, Tyskland, 55131
- Novartis Investigative Site
-
Ulm, Tyskland, 89081
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Villingen-Schwenningen, Baden-Wurttemberg, Tyskland, 78052
- Novartis Investigative Site
-
-
Bavaria
-
Munich, Bavaria, Tyskland, 81377
- Novartis Investigative Site
-
Würzburg, Bavaria, Tyskland, 97080
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Tyskland, 60431
- Novartis Investigative Site
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Tyskland, 37075
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Tyskland, 42010
- Novartis Investigative Site
-
Geilenkirchen, North Rhine-Westphalia, Tyskland, 52511
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Tyskland, 01307
- Novartis Investigative Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Beskrivning
Inklusionskriterier:
- Patienter som för närvarande genomgår lipoproteinaferes för isolerad Lp(a) på ett veckoschema i Tyskland i ≥ 12 månader före screening med minst 40 sessioner under de senaste 52 veckorna före randomisering
- Lipoprotein(a) (Lp(a))> 60 mg/dL vid screening
- Spontan tidigare hjärtinfarkt (MI): ≥ 3 månader från screeningbesöket till ≤ 10 år före screeningbesöket, och/eller
- Ischemisk stroke: ≥ 3 månader från screeningbesöket till ≤ 10 år före screeningbesöket, och/eller
- Kliniskt signifikant symtomatisk perifer artärsjukdom (PAD)
Exklusions kriterier:
- Okontrollerad hypertoni
- Hjärtsvikt New York Heart Association (NYHA) klass IV
- Historik om malignitet i något organsystem
- Historik av hemorragisk stroke eller annan större blödning
- Antal blodplättar
- Aktiv leversjukdom eller leverdysfunktion
- Betydande njursjukdom
- Gravida eller ammande kvinnor
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Pelacarsen (TQJ230)
Pelacarsen (TQJ230) 80 mg s.c.
Q4W
|
Pelacarsen (TQJ230) 80 mg s.c.
Q4W
Andra namn:
|
|
Placebo-jämförare: Placebo
Placebo to Pelacarsen s.c. Q4W
|
Placebo till Pelacarsen
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule
Tidsram: Up to Week 52
|
Rate (proportion) of apheresis sessions was calculated as the number of actual lipoprotein apheresis (LA) sessions received, divided by the number of planned LA sessions during the 52-week period, which is 52 for patients who completed all study visits, or pro-rated for those who discontinued early.
This rate could range from 0 to 1, with 0 indicating that the patient had skipped all planned LA sessions, and 1 indicating that the patient had received all planned sessions.
Multiple imputation for missing Lp(a) data was performed, and missing apheresis data was imputed.
|
Up to Week 52
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to Lipoprotein Apheresis Avoidance
Tidsram: From randomization up to Week 52
|
Lipoprotein apheresis avoidance is defined as at least 24 consecutive weeks of no lipoprotein apheresis until end of study.
|
From randomization up to Week 52
|
|
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 12 to Week 52
Tidsram: Week 12 up to Week 52
|
Total lipoprotein apheresis avoidance is defined as no apheresis performed from Week 12 to Week 52.
|
Week 12 up to Week 52
|
|
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as mg/dL
Tidsram: Baseline, week 52
|
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as particle mass (mg/dL).
Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
|
Baseline, week 52
|
|
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as Nmol/L
Tidsram: Baseline, week 52
|
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as molar concentration (nmol/L).
Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
|
Baseline, week 52
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of Lipoprotein Apheresis Sessions From Week 12 to Week 52 and Week 24 to Week 52 Normalized to the Weekly Lipoprotein Apheresis Schedule
Tidsram: Week 12 to 52, Week 24 to 52
|
Rate (proportion) of apheresis sessions is calculated using the following formula: the total number of apheresis sessions performed over the double-blinded treatment period/total weeks from Week12 to Week52 or total weeks from Week24 to Week52.
Multiple imputation for missing Lp(a) data was performed and missing apheresis data were imputed.
|
Week 12 to 52, Week 24 to 52
|
|
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 24 to Week 52
Tidsram: Week 24 to Week 52
|
Number of participants with no apheresis performed between week 24 to week 52.
|
Week 24 to Week 52
|
|
Time-averaged Lp(a) Levels Reported as mg/dL
Tidsram: Baseline, Week 52
|
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
|
Baseline, Week 52
|
|
Time-averaged Lp(a) Levels Reported as Nmol/L
Tidsram: Baseline, Week 52
|
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
|
Baseline, Week 52
|
|
Percentage Change in Total Cholesterol, LDL-C, High-density Lipoprotein-Cholesterol (HDL-C), Non-HDL-C, Very-low-density Lipoprotein-Cholesterol (VLDL-C), apoB and Triglycerides (Pre- Lipoprotein Apheresis) From Baseline to Week 52
Tidsram: Baseline, Week 52
|
Evaluate the change in expanded lipid profile parameters measured in mg/dL
|
Baseline, Week 52
|
|
Change From Baseline to Week 52 in the Physical Health Summary Score for the SF-36 Questionnaire
Tidsram: Baseline, Week 52
|
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement. |
Baseline, Week 52
|
|
Change From Baseline to Week 52 in the Mental Health Summary Score for the SF-36 Questionnaire
Tidsram: Baseline, Week 52
|
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement. |
Baseline, Week 52
|
|
Patient Preference Questionnaire
Tidsram: Baseline, Week 52
|
Participants were asked for their treatment preference between weekly lipoprotein apheresis or monthly self-injection.
The number of participants that prefer each option at baseline and 52 weeks is reported.
|
Baseline, Week 52
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CTQJ230A12302
- 2021-003059-41 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .